Lambda Therapeutic Research Ltd. is a leading Multinational Clinical Research Organisation (CRO), headquartered in Ahmedabad (India), providing full drug development services. Since its' inception in 1999, Lambda has always keep pace with technological advancement in clinical research industry to cater its valuable clients with utmost quality and satisfaction. Lambda has recently installed a new LC-MS/MS, XEVO TQS, one of the most sensitive LC-MS / MS Platform available in the market at present, adding new dimension to Bioanlytical Services which will be helpful for sensitive assays.
Lambda became the first India based CRO to go totally paperless by implementing its technologically robust e-clinical solutions in Clinical Trials including across niche challenging areas like PharmacoVigilance and Medical Imaging.
- Clinical Trial Management System – BizNET
Lambda became the first India CRO to implement EDC / eCRF solution across its Phase I to Phase IV clinical trials. Lambda's Clinical Trial Management System is developed in compliance with 21CFR Part11 having added layer of security and controls with logical edit checks. The system is developed with an intention to keep it user friendly for easy adaptability to reduce the time and produce high quality data with assured authenticity.
- PharmacoVigilance – PVNet
Lambda's PharmacoVigilance System Platform is regulatory compliant and comprehensive safety and risk management module allows complex analysis and querying, thereby triggered to manage extensive and quickly growing safety datasets.
- Medical Imaging – Cent-Re-View
Lambda's robust, validated and regulatory compliant Central Imaging Review Application generates complete Audit Trail and its Automated, Sturdy and Smart features assures zero manual errors having in-built error scanning as well as customizable for Oncology, Musculoskeletal, CNS, CVS etc. specific assessment criteria including RECIST along with Hybrid Configuration.
Dr. Manish Sharma, Vice President, Lambda Therapeutic Research, India, will be sharing his views at Pharma Trials World Asia 2012 this March about "Optimising Clinical Trials in Asian Powerhouses"